z-logo
Premium
The group 2 innate lymphoid cell ( ILC 2) regulatory network and its underlying mechanisms
Author(s) -
Kabata Hiroki,
Moro Kazuyo,
Koyasu Shigeo
Publication year - 2018
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/imr.12706
Subject(s) - nfat , biology , microbiology and biotechnology , mapk/erk pathway , innate lymphoid cell , signal transduction , interleukin 10 , immunology , innate immune system , immune system , transcription factor , biochemistry , gene
Summary Group 2 innate lymphoid cells ( ILC 2s) play critical roles in the induction of type 2 inflammation, response to parasite infection, metabolic homeostasis, and tissue repair. These multifunctional roles of ILC 2s are tightly controlled by complex regulatory systems in the local microenvironment, the disruption of which may cause various health problems. This review summarizes up‐to‐date knowledge regarding positive and negative regulators for ILC 2s based on their function and signaling pathways, including activating cytokines ( IL ‐33, IL ‐25; MAPK , NF ‐κB pathways), co‐stimulatory cytokines ( IL ‐2, IL ‐7, IL ‐9, TSLP ; STAT 5, IL ‐4; STAT 6, TNF superfamily; MAPK , NF ‐κB pathways), suppressive cytokines (type1 IFN s, IFN ‐γ, IL ‐27; STAT 1, IL ‐10, TGF ‐β), transdifferentiation cytokines ( IL ‐12; STAT 4, IL ‐1β, IL ‐18), lipid mediators ( LTC 4, LTD 4, LTE 4, PGD 2; Ca 2+ ‐ NFAT pathways, PGE 2, PGI 2; AC / cAMP / PKA pathways, LXA 4, LTB 4), neuropeptides ( NMU ; Ca 2+ ‐ NFAT , MAPK pathways, VIP , CGRP , catecholamine, acetylcholine), sex hormones (androgen, estrogen), nutrients (butyrate; HDAC inhibitors, vitamins), and cell‐to‐cell interactions ( ICOSL ‐ ICOS ; STAT 5, B7‐H6‐ NK p30, E‐cadherin‐ KLRG 1). This comprehensive review affords a better understanding of the regulatory network system for ILC 2s, providing impetus to develop new treatment strategies for ILC 2‐related health problems.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here